Academic Journal
Προβολή σε EDS

The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial.
Συγγραφείς: Kirkland AE; Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, USA. kirklaan@musc.edu., Browning BD; Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, USA., Meredith LR; Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, USA., Robertson E; Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, USA., Herring C; Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, USA., Tomko RL; Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, USA., Gray KM; Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, USA., Squeglia LM; Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Charleston, SC, USA.
Πηγή: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2025 Sep; Vol. 50 (10), pp. 1482-1492. Date of Electronic Publication: 2025 Jun 11.
Τύπος έκδοσης: Journal Article; Randomized Controlled Trial
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8904907 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1740-634X (Electronic) Linking ISSN: 0893133X NLM ISO Abbreviation: Neuropsychopharmacology Subsets: MEDLINE
Imprint Name(s): Publication: 2003- : London : Nature Publishing Group
Original Publication: [New York, NY] : Elsevier, [c1987-
Ιατρικοί όροι (MeSH): Cannabidiol*/pharmacology , Cannabidiol*/therapeutic use , Alcoholism*/drug therapy , Alcoholism*/physiopathology , Alcoholism*/diagnostic imaging , Alcoholism*/metabolism , Alcoholism*/psychology , Gyrus Cinguli*/drug effects , Gyrus Cinguli*/diagnostic imaging , Gyrus Cinguli*/metabolism , Brain*/drug effects , Brain*/diagnostic imaging , Brain*/metabolism, Glutamic Acid/metabolism ; gamma-Aminobutyric Acid/metabolism ; Glutamine/metabolism ; Craving/drug effects ; Heart Rate/drug effects ; Humans ; Female ; Double-Blind Method ; Adolescent ; Male ; Young Adult ; Magnetic Resonance Imaging
Περίληψη: Novel treatment evaluation for youth with alcohol use disorder (AUD) is needed. Cannabidiol (CBD), a constituent of the Cannabis sativa plant, may be a promising candidate pharmacotherapy due to its potential therapeutic properties and preclinical research suggesting it decreases alcohol use. Due to limited data in humans, rigorous screening of the acute neural, psychophysiological, and alcohol-related effects of CBD is indicated to assess its viability as a potential treatment for youth AUD. Using a within-subjects, randomized, double-blind, placebo-controlled design, we tested acute multi-modal effects of CBD (600 mg) in non-treatment seeking youth with AUD (N = 36; ages 17-22; 69% female). Outcomes included (1) glutamate+glutamine (Glx) and GABA levels in the anterior cingulate cortex measured with proton magnetic resonance spectroscopy; (2) whole-brain and a priori region-of-interest neural alcohol cue-reactivity measured with functional MRI; (3) psychophysiological response to alcohol olfactory cues measured by self-reported acute alcohol craving, heart rate variability, and skin conductance; and (4) alcohol use. No CBD-associated adverse events were observed. There were no effects of acute CBD administration, compared to placebo, on any outcomes of interest. This is the first adequately powered medication screening study for the use of CBD in youth with AUD. We did not detect significant effects of CBD on neurometabolic, neurobehavioral, psychophysiological, or alcohol use outcomes in this sample. Future studies may benefit from chronic administration to better understand substance-related effects.Clinicaltrials.gov NCT05317546 https://clinicaltrials.gov/study/NCT05317546.
(© 2025. The Author(s).)
Competing Interests: Competing interests: Dr. Kevin Gray reports having received consultation fees from Achieve Life Sciences and Indivior, and research support from Aelis Farma. All other authors report no potential competing interests.
References: Eur Arch Psychiatry Clin Neurosci. 2025 Mar 18;:. (PMID: 40102270)
Exp Clin Psychopharmacol. 2019 Aug;27(4):359-369. (PMID: 31120285)
Addict Behav. 2024 Jun;153:107996. (PMID: 38394959)
Biol Psychiatry. 2008 Dec 1;64(11):966-73. (PMID: 18589404)
Cannabis Cannabinoid Res. 2022 Apr;7(2):161-169. (PMID: 33998889)
J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686)
Psychol Addict Behav. 2021 Sep;35(6):749-759. (PMID: 33764086)
Arch Gen Psychiatry. 2012 Jan;69(1):27-36. (PMID: 22213786)
Alcohol Clin Exp Res. 2019 Oct;43(10):2038-2056. (PMID: 31386215)
J Consult Clin Psychol. 2011 Aug;79(4):433-40. (PMID: 21728400)
J Psychopharmacol. 2019 Sep;33(9):1141-1148. (PMID: 31237191)
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. (PMID: 9881538)
Mol Psychiatry. 2011 Oct;16(10):974-86. (PMID: 21519339)
Mol Psychiatry. 2025 Jun;30(6):2612-2619. (PMID: 39668256)
Addict Biol. 2013 Jan;18(1):121-33. (PMID: 22574861)
Pharmacogenomics J. 2007 Dec;7(6):380-5. (PMID: 17189959)
Crit Rev Food Sci Nutr. 2019;59(4):676-692. (PMID: 28980828)
Neuropsychopharmacology. 2023 Jul;48(8):1184-1193. (PMID: 36878996)
Psychiatry Res. 2022 Feb;308:114347. (PMID: 34952255)
Alcohol Clin Exp Res (Hoboken). 2023 Apr;47(4):668-677. (PMID: 36855285)
Transl Psychiatry. 2020 Sep 13;10(1):311. (PMID: 32921794)
Pharmacol Res. 2017 May;119:358-370. (PMID: 28249817)
Addict Biol. 2020 May;25(3):e12765. (PMID: 31074060)
Eur J Pharmacol. 2011 Mar 25;655(1-3):38-45. (PMID: 21266173)
Subst Abuse. 2015 May 21;9:33-8. (PMID: 26056464)
Neuropsychopharmacology. 2019 Jul;44(8):1398-1405. (PMID: 30758329)
Arch Gen Psychiatry. 2012 Apr;69(4):390-8. (PMID: 22474107)
J Pharmacol Exp Ther. 2005 Aug;314(2):780-8. (PMID: 15878999)
J Subst Abuse Treat. 2015 Apr;51:1-18. (PMID: 25300577)
Neuropsychopharmacology. 2018 Sep;43(10):2036-2045. (PMID: 29686308)
J Clin Psychiatry. 2010 Mar;71(3):313-26. (PMID: 20331933)
Br J Pharmacol. 2008 Jan;153(2):199-215. (PMID: 17828291)
Neurosci Lett. 2021 Jan 23;744:135594. (PMID: 33388355)
Physiol Rev. 2016 Oct;96(4):1593-659. (PMID: 27630175)
CNS Neurol Disord Drug Targets. 2015;14(6):745-56. (PMID: 26022265)
Alcohol Clin Exp Res (Hoboken). 2024 Sep;48(9):1772-1783. (PMID: 38960894)
J Child Adolesc Psychopharmacol. 2019 Aug;29(7):559-572. (PMID: 31009234)
Addict Biol. 2014 Sep;19(5):941-54. (PMID: 23489253)
Mol Psychiatry. 2022 Aug;27(8):3223-3236. (PMID: 35508628)
JAMA. 2007 Apr 18;297(15):1683-96. (PMID: 17440145)
Drug Alcohol Depend. 2020 Apr 1;209:107897. (PMID: 32058245)
J Psychopharmacol. 2021 Jul;35(7):814-822. (PMID: 33860709)
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:255-261. (PMID: 29885468)
Br J Pharmacol. 2018 Aug;175(16):3369-3378. (PMID: 29859012)
Alcohol Clin Exp Res. 2019 Apr;43(4):550-563. (PMID: 30698831)
Addiction. 2000 Apr;95(4):601-12. (PMID: 10829335)
Drug Alcohol Depend. 2012 Sep 1;125(1-2):27-36. (PMID: 22503310)
Alcohol Clin Exp Res. 2014 Apr;38(4):969-79. (PMID: 24512596)
Addict Biol. 2016 Jan;21(1):171-82. (PMID: 25353306)
Am J Drug Alcohol Abuse. 2015;41(4):300-8. (PMID: 26125586)
Arch Pediatr Adolesc Med. 2010 Jan;164(1):85-91. (PMID: 20048247)
Br J Pharmacol. 2015 Oct;172(20):4790-805. (PMID: 26218440)
CNS Drugs. 2018 Nov;32(11):1053-1067. (PMID: 30374683)
Arch Gen Psychiatry. 2003 Jul;60(7):727-35. (PMID: 12860777)
J Stud Alcohol. 2005 May;66(3):354-60. (PMID: 16047524)
Psychol Med. 2021 Mar;51(4):596-606. (PMID: 31994476)
Neurotoxicology. 2015 Sep;50:116-21. (PMID: 26283212)
Drug Alcohol Depend. 2024 Apr 1;257:111254. (PMID: 38457964)
Addict Biol. 2016 Jan;21(1):3-22. (PMID: 26435524)
Neuropsychopharmacology. 2011 Jun;36(7):1340-8. (PMID: 21412224)
Addict Biol. 2018 Jan;23(1):154-164. (PMID: 28194850)
Prog Chem Org Nat Prod. 2017;103:1-36. (PMID: 28120229)
Addict Behav. 2004 Jan;29(1):33-50. (PMID: 14667419)
Drug Saf. 2020 Nov;43(11):1141-1156. (PMID: 32705447)
Clin Psychol Rev. 2006 Mar;26(2):149-61. (PMID: 16364524)
Alcohol Clin Exp Res (Hoboken). 2025 Feb;49(2):448-459. (PMID: 39891614)
NMR Biomed. 2021 May;34(5):e4484. (PMID: 33559967)
Br J Pharmacol. 2007 Mar;150(5):613-23. (PMID: 17245363)
Neuropharmacology. 2016 Apr;103:16-26. (PMID: 26711860)
Am J Drug Alcohol Abuse. 2019;45(1):26-41. (PMID: 29513609)
J Biol Chem. 2015 Apr 3;290(14):8711-21. (PMID: 25666611)
Alcohol Clin Exp Res. 2018 Sep;42(9):1612-1622. (PMID: 29969156)
Experientia. 1981 Oct 15;37(10):1090-2. (PMID: 6273208)
Neuropsychopharmacology. 2010 Feb;35(3):764-74. (PMID: 19924114)
Pharmacol Biochem Behav. 2005 Jun;81(2):369-80. (PMID: 15939463)
Brain Imaging Behav. 2018 Aug;12(4):931-941. (PMID: 28801730)
Neuron. 2018 Jun 6;98(5):886-903. (PMID: 29879391)
Pharmacol Biochem Behav. 2013 Oct;111:120-7. (PMID: 24012796)
Addict Behav. 2015 Jul;46:45-52. (PMID: 25796007)
Alcohol Clin Exp Res. 2013 Jan;37 Suppl 1:E161-71. (PMID: 23078363)
Biol Psychiatry. 2012 Jun 1;71(11):1015-21. (PMID: 21907974)
Biochem Pharmacol. 2018 Nov;157:108-121. (PMID: 30217570)
Am J Psychiatry. 2019 Nov 1;176(11):911-922. (PMID: 31109198)
Neuropsychology. 2019 Sep;33(6):781-794. (PMID: 31448946)
J Neurosci. 2004 Sep 22;24(38):8245-52. (PMID: 15385608)
Complement Ther Med. 2003 Mar;11(1):28-32. (PMID: 12667972)
Acta Pharmacol Sin. 2014 Aug;35(8):981-93. (PMID: 25066321)
Neurosci Biobehav Rev. 2014 Jan;38:1-16. (PMID: 24211373)
Arch Gen Psychiatry. 2009 Jan;66(1):95-105. (PMID: 19124693)
Alcohol Clin Exp Res. 2020 Feb;44(2):340-353. (PMID: 31803950)
Alcohol Clin Exp Res (Hoboken). 2023 Sep;47(9):1629-1645. (PMID: 37423771)
JAMA Psychiatry. 2024 Apr 01;81(4):414-425. (PMID: 38324323)
Eur Neuropsychopharmacol. 2018 Jul;28(7):841-849. (PMID: 29887287)
Drug Test Anal. 2023 Mar;15(3):334-344. (PMID: 36478641)
Br J Pharmacol. 2019 May;176(10):1455-1469. (PMID: 29981240)
Naunyn Schmiedebergs Arch Pharmacol. 2006 Feb;372(5):354-61. (PMID: 16489449)
Grant Information: T32 DA007288 United States DA NIDA NIH HHS; K01 AA031745 United States AA NIAAA NIH HHS; R21 AA030114 United States AA NIAAA NIH HHS; DA007288 U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA); K01AA031745 U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA); K24AA031052 U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA); K24 AA031052 United States AA NIAAA NIH HHS; R21AA030114 U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Molecular Sequence: ClinicalTrials.gov NCT05317546
Substance Nomenclature: 19GBJ60SN5 (Cannabidiol)
3KX376GY7L (Glutamic Acid)
56-12-2 (gamma-Aminobutyric Acid)
0RH81L854J (Glutamine)
Entry Date(s): Date Created: 20250611 Date Completed: 20250812 Latest Revision: 20250814
Update Code: 20260130
PubMed Central ID: PMC12339998
DOI: 10.1038/s41386-025-02141-z
PMID: 40500407
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1740-634X
DOI:10.1038/s41386-025-02141-z